Your search history is turned on.
Date: March 19, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - Notice_of_Change.DOC Notice of Change in Corporate Structure pursuant to Section 4.9 of National Instrument 51-102 1. Names of the Parties to the Transaction: Cascadian Therapeutics, Inc. (Cascadian) and Seattle Genetics, Inc., (Seattle Genetics) completed a transaction (the Transaction) under the General Corporation Law of the State of ...
Date: March 9, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2018 CASCADIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33882 26-08...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CASCADIAN THERAPEUTICS, INC. (Name of Subject Company (Issuer)) VALLEY ACQUISITION SUB, INC. (Offeror) SEATTLE GENETICS, I...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9/A (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) CASCADIAN THERAPEUTICS, INC. (Name of Subject Company) CASCADIAN THERAPEUTICS, INC. (Name of Persons Filing Statement) C...
Date: March 8, 2018 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
printmgr file UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION...
printmgr file EXHIBIT 31.2 CERTIFICATION I, Julia M. Eastland, certify that: 1. I have reviewed this annual report on Form 10-K of Cascadian Therapeutics, Inc., (the Registrant); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circ...
printmgr file EXHIBIT 31.1 CERTIFICATION I, Scott D. Myers, certify that: 1. I have reviewed this annual report on Form 10-K of Cascadian Therapeutics, Inc., (the Registrant); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circums...
printmgr file ITEM 7. Managements Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements ...
Microsoft Word - 25906742_2 25906742_2|NATDOCS FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, Julia M. Eastland, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the Form) being submitted hereunder to the Alberta Securities Commission and certify that...
Microsoft Word - 25908814_2 ...